Financial Performance - The company's revenue for Q1 2024 was ¥528,463,890.64, a decrease of 16.65% compared to ¥634,047,833.60 in the same period last year[7] - Net profit attributable to shareholders was ¥32,593,338.56, down 22.58% from ¥42,101,946.61 year-on-year[7] - Total operating revenue for Q1 2024 was $528.46 million, a decrease of 16.66% from $634.05 million in the same period last year[37] - Net profit for Q1 2024 was $32.10 million, down 23.4% compared to $41.85 million in Q1 2023[41] - Total comprehensive income attributable to the parent company was ¥32,593,338.56, down from ¥42,101,946.61 in the previous period, representing a decrease of approximately 22.5%[43] Cash Flow - The net cash flow from operating activities was ¥28,489,229.96, representing a significant decline of 82.13% from ¥159,451,304.75 in the previous year[7] - Cash inflow from operating activities totaled ¥440,566,222.35, down 11.4% from ¥497,507,810.56 in the previous period[44] - Cash outflow from operating activities increased to ¥412,076,992.39, compared to ¥338,056,505.81 in the previous period, marking a rise of 21.9%[44] - Net cash flow from investing activities was -¥58,747,912.25, a decline from a positive cash flow of ¥81,685,962.84 in the previous period[46] - Cash inflow from financing activities increased to ¥1,175,600,000.00, up from ¥966,107,488.00 in the previous period, reflecting a growth of 21.6%[46] - Cash outflow from financing activities rose to ¥938,615,931.61, compared to ¥362,399,978.71 in the previous period, indicating an increase of 159.2%[46] - The ending balance of cash and cash equivalents was ¥1,459,324,838.28, down from ¥1,869,798,598.82 in the previous period, a decrease of approximately 22%[46] Assets and Liabilities - The total assets at the end of the reporting period were ¥7,650,432,164.42, an increase of 1.73% from ¥7,520,092,953.12 at the end of the previous year[7] - Total liabilities rose to $2.11 billion, compared to $1.92 billion in the previous year, indicating a growth of 10.5%[36] - The company's equity attributable to shareholders decreased by 1.16% to ¥5,541,569,876.91 from ¥5,606,352,298.36[7] - The company maintained a stable equity position with total equity at $5.54 billion, slightly down from $5.61 billion[36] Shareholder Information - Total number of common shareholders at the end of the reporting period is 30,172[18] - Zhejiang Donggang Industrial Co., Ltd. holds 32.37% of shares, totaling 523,982,587 shares[22] - Wang Yunfu, a natural person, holds 7.34% of shares, totaling 118,800,000 shares, with 38,000,000 shares pledged[22] - As of March 31, 2024, the company has repurchased 21,874,798 shares, accounting for 1.3514% of total share capital[27] - The total amount for the share repurchase plan is between RMB 150 million and RMB 300 million, with a maximum repurchase price of RMB 8.92 per share[26] - The chairman, Wang Yangchao, has increased his holdings by 696,500 shares, accounting for 0.0430% of total shares[26] Operational Metrics - The basic and diluted earnings per share remained unchanged at ¥0.02[7] - Non-recurring gains and losses totaled -¥663,358.00, primarily due to foreign exchange hedging losses[8] - The company reported a significant increase in prepayments by 74.96%, amounting to ¥38,986,801.14 compared to ¥22,283,130.66 in the previous year[13] - The company experienced a 92.63% reduction in trading financial liabilities, decreasing to ¥2,682,000.00 from ¥36,370,389.61[13] - Accounts receivable increased to RMB 477,138,467.57 from RMB 424,703,017.66[29] - Inventory decreased to RMB 636,368,872.33 from RMB 702,270,769.40[29] - The company reported a significant increase in research and development expenses, totaling $30.01 million, compared to $31.04 million in the previous year[37] - Investment income showed a loss of $6.03 million, contrasting with a gain of $20.09 million in the prior year[41] Strategic Initiatives - The company is focusing on market expansion and new product development as part of its strategic initiatives moving forward[39] - The company plans to continue its share repurchase based on market conditions within the specified period[27] Audit Information - The company did not undergo an audit for the first quarter report[48]

浙江海翔药业股份有限公司 2023年度内部控制自我评价报告 浙江海翔药业股份有限公司全体股东： 根据《企业内部控制基本规范》及《深圳证券交易所上市公司自律监管指引 第1号——主板上市公司规范运作》等内部控制监管要求（以下简称企业内部控 制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部 控制日常监督和专项监督的基础上，我们对公司截至2023年12月31日（内部控制 评价报告基准日）的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于 ...

浙江海翔药业股份有限公司 股东大会议事规则 （2024 年 4 月修订） 第一章 总则 第一条 为保证浙江海翔药业股份有限公司（以下简称"公司"）股东大会的 正常秩序和决议的合法性，提高股东大会议事效率，维护全体股东的合法权益， 依据《中华人民共和国公司法》（下简称"《公司法》"）、《上市公司股东大会规则》 （下简称"《股东大会规则》"）、《上市公司治理准则》（下简称"《治理准则》"） 及《浙江海翔药业股份有限公司章程》（以下简称"《公司章程》"）的有关规定， 制定本议事规则。 第二条 公司应当严格按照法律、行政法规、本规则及公司章程的相关规定 召开股东大会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东大会。公司全体董事应 当勤勉尽责，确保股东大会正常召开和依法行使职权。 第三条 股东大会由公司全体股东组成，是公司的最高权力机构。股东大会 应当在《公司法》和《公司章程》规定的范围内依法行使下列职权： （一）选举和更换董事、监事，决定有关董事、监事的报酬事项； （二）审议批准董事会的报告； （三）审议批准监事会的报告； （四）审议批准公司的利润分配方案和弥补亏损方案； （五）对公司 ...

证券代码：002099 证券简称：海翔药业 公告编号：2024-032 浙江海翔药业股份有限公司 浙江海翔药业股份有限公司（以下简称"公司"）已于2024年4月29日披露 了2023年年度报告，为便于广大投资者深入全面地了解公司情况，公司将举办投 资者接待日活动，现将有关事项公告如下： 一、接待时间 2024年5月20日下午15:00-17:00。 二、接待地点 浙江省台州市椒江区岩头工业区海虹路71号台州前进会议室 三、预约方式 欲参与本次投资者接待日活动的投资者请于2024年5月15日前与公司投资发 展部联系，以便接待登记和安排。 联系人：蒋如东 关于举办投资者接待日的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 四、公司参与人员 董事长王扬超先生，总经理许国睿先生，财务总监姚冰先生，董事会秘书王 晓洋女士（如有特殊情况，参与人员会有调整）。 五、注意事项 浙江海翔药业股份有限公司 电 话：0576-89088166 传 真：0576-89088128 邮 箱：stock@hisoar.com 地 址：浙江省台州市椒江区岩头工业区海虹路71号公司投 ...

Financial Measurement and Reporting - The company measures financial assets and liabilities at fair value, with changes recognized in profit or loss for financial liabilities designated at fair value[1]. - Financial liabilities are subsequently measured at fair value, with gains or losses from changes in credit risk recognized in other comprehensive income[1]. - The company uses expected credit losses to assess impairment for financial assets measured at amortized cost and certain other financial instruments[6]. - The expected credit loss rates for accounts receivable are based on historical loss experience and future economic forecasts, with rates of 5% for up to 1 year, 30% for 1-2 years, 80% for 2-3 years, and 100% for over 3 years[11]. - The company applies a single financial instrument or portfolio basis to assess expected credit risk and measure expected credit losses[9]. - The company recognizes cumulative changes in expected credit losses for credit-impaired financial assets only from the date of initial recognition[7]. - The company will remeasure the remaining equity at fair value on the date of losing control over the subsidiary, with the investment income recognized in the current period[22]. - The company recognizes contract assets or liabilities based on the relationship between fulfilling obligations and customer payments, netting them in the balance sheet[46]. - Employee compensation liabilities are recognized based on the best estimate of expenditures required to fulfill current obligations[51]. - The company will account for share-based payments, both equity-settled and cash-settled, in accordance with relevant accounting standards[52]. Inventory and Asset Management - Inventory is measured at the lower of cost and net realizable value, with provisions for inventory write-downs recognized when costs exceed net realizable values[15]. - The company's raw materials have a book balance of ¥184,930,123, with a provision for inventory impairment of ¥24,970,003.6, resulting in a net book value of ¥159,960,120[60]. - The total inventory balance is ¥823,197,836, with an impairment provision of ¥120,927,066, leading to a net book value of ¥702,270,769[60]. - The company’s inventory includes work-in-progress valued at ¥38, with a provision for impairment of ¥6, indicating ongoing production activities[60]. - The company has established a sound inventory management system to mitigate risks associated with inventory shortages and excesses, ensuring stable and healthy development[199]. Revenue Recognition and Financial Performance - The company recognizes revenue based on the progress of performance obligations, with revenue confirmed upon the transfer of control of goods to customers[56]. - The company’s sales of raw pharmaceutical materials and intermediates are recognized at the point of delivery to the buyer for domestic sales and upon customs clearance for exports[59]. - The company reported a total revenue for the year was approximately ¥2.17 billion, a decrease from ¥2.70 billion in the previous year, representing a decline of about 19.7%[81]. - The net profit attributable to shareholders for the first quarter was approximately ¥42.10 million, while the second quarter showed a loss of ¥22.93 million, indicating significant volatility in earnings[81]. - The company reported a net profit loss of approximately ¥381.47 million in the fourth quarter, highlighting ongoing financial challenges[81]. - The revenue for the first quarter was approximately ¥634.05 million, while the fourth quarter revenue was approximately ¥495.26 million, showing a downward trend throughout the year[81]. - The company’s direct sales model generated revenue of CNY 2,171,886,860, down 19.68% year-over-year, with a gross margin of 14.03%[141]. Investment and Capital Expenditure - The company determines the initial investment cost for business combinations based on the fair value of the consideration paid on the acquisition date[17]. - Borrowing costs can be capitalized when certain conditions are met, including the occurrence of asset expenditures and borrowing costs[26]. - If the construction or production of capitalizable assets is interrupted for more than three months, capitalization of borrowing costs will be suspended[33]. - The total investment amount for the reporting period was ¥345,483,319.56, a decrease of 65.22% compared to ¥993,398,708.20 in the same period last year[176]. - The company has committed a total investment of CNY 40,000 million for the Active Pharmaceutical Ingredients (API) and intermediates CMO center expansion project, with an adjusted total investment of CNY 28,440.36 million, achieving an investment progress of 102.85%[191]. - The pharmaceutical comprehensive R&D center project has an adjusted total investment of CNY 6,875.87 million, with a 100% investment progress achieved[191]. - The company has invested CNY 1,237.1 million in the headquarters research institute project, achieving an investment progress of 11.73%[191]. - The environmental protection facility renovation project has an adjusted total investment of CNY 14,000 million, with an investment progress of 105.75%[191]. Market and Strategic Developments - The company has established a strategic partnership with Boehringer Ingelheim, resulting in a doubling of orders compared to the previous year[120]. - The global pharmaceutical market is projected to grow at an annual rate of 3%-6%, reaching $1.9 trillion by 2027, providing growth opportunities for the company[123]. - The company is focusing on high-performance environmentally friendly dyes, with a product line that includes reactive blue dyes known for their superior performance[122]. - The domestic dye industry is facing challenges with reduced demand and increased competition, necessitating a focus on high-quality development strategies[124]. - The company is actively pursuing the development of functional dyes and specialty pigments to address high-quality development constraints in the industry[125]. - The company aims to enhance its capabilities in contract manufacturing and development services (CMO/CDMO) to capture opportunities in clinical phases II and III[120]. - The company is committed to integrating green and intelligent development in its dye and pigment production processes to align with national industrial policies[124]. - The company is actively expanding its international market presence, with significant sales in the US, Europe, Japan, and India[129]. Research and Development - Direct costs related to research and development activities include materials, fuel, and maintenance of equipment used in R&D[37]. - R&D investment amounted to 115.56 million yuan, representing 5.32% of total revenue, with 342 R&D personnel[135]. - The company has submitted 6 new patent applications and received 4 patent grants during the reporting period[135]. Financial Position and Liabilities - Cash and cash equivalents at the end of the period were CNY 1,420,570,794.77, representing 18.89% of total assets[172]. - Accounts receivable at the end of the period amounted to CNY 424,703,017.66, accounting for 5.65% of total assets[172]. - Inventory at the end of the period was CNY 702,270,769.40, representing 9.34% of total assets, with a decrease attributed to inventory impairment[172]. - The total amount of short-term borrowings was CNY 8,610,000, accounting for 13.68% of total liabilities[172]. - The total amount of long-term borrowings decreased significantly due to repayments during the period[172]. - The company's financial assets totaled ¥537,441,287.63, with a decrease of ¥72,940,597.78 during the reporting period[174]. - The company's financial liabilities amounted to ¥23,480,126.06, with an increase of ¥32,024,589.60 during the reporting period[174]. - The total amount of pledged bank acceptance bills at the end of the period was CNY 400,383,446.04[159]. - The total amount of other receivables written off during the period was CNY 22,728,178.50, accounting for 51.00% of the total other receivables[162]. - The total bad debt provision amounted to CNY 20,437,512.26, representing 100% of the expected credit loss model for the first stage[157]. Compliance and Governance - The company has no discrepancies in net profit and net assets between international accounting standards and Chinese accounting standards during the reporting period[111]. - The company’s major accounting firm is Tianjian Accounting Firm, which is responsible for auditing its financial statements[79]. - The independent directors support the company's foreign exchange hedging activities, emphasizing that they are closely related to the company's operational needs and do not involve speculative risks[66]. - The company disclosed an ESG report for the first time, highlighting achievements in environmental protection, employee rights, and social responsibility[138].

海翔药业公司章程 浙江海翔药业股份有限公司 公司章程 （2024 年 4 月修订） 1 海翔药业公司章程 目 录 2 第一章 总则 第二章 经营宗旨和范围 第三章 股份 第一节 股份发行 第二节 股份增减和回购 第三节 股份转让 第四章 股东及股东大会 第一节 股东 第二节 股东大会的一般规定 第三节 股东大会的召集 第四节 股东大会的提案与通知 第五节 股东大会的召开 第六节 股东大会的表决和决议 第五章 董事会 第一节 董事 第二节 董事会 第六章 总经理及其他高级管理人员 第七章 监事会 第一节 监事 第二节 监事会 第八章 财务会计制度、利润分配和审计 第一节 财务会计制度 第二节 内部审计 第三节 会计事务所的聘任 第九章 通知和公告 第一节 通知 第二节 公告 海翔药业公司章程 第十章 合并、分立、增资、减资、解散和清算 第一节 合并、分立增资和减资 第二节 解散和清算 3 第十一章 修改章程 第十二章 附则 海翔药业公司章程 第一章 总 则 第一条 为维护公司、股东和债权人的合法权益，规范公司的组织和行为，根据 《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简 称 ...

浙江海翔药业股份有限公司 薪酬与考核委员会议事规则 （2024 年 4 月修订） 第五条 薪酬与考核委员会委员由董事长、二分之一以上独立董事或者全体 董事的三分之一提名,并由董事会选举产生。 第六条 薪酬与考核委员会设主任委员一名，由独立董事委员担任，负责主 持委员会工作；主任委员在委员内选举，并报请董事会批准产生。 第一章 总则 第一条 为建立、完善浙江海翔药业股份有限公司(以下简称"公司")包括 董事、监事、高级管理人员在内的各级员工业绩考核与评价体系，制订科学、 有效的薪酬管理制度，实施公司的人才开发与利用战略。根据《中华人民共和 国公司法》、《上市公司治理准则》、《公司章程》及其他有关规定,公司特设立董 事会薪酬与考核委员会,并制定本议事规则。 第二条 薪酬与考核委员会是董事会设立的专门工作机构，主要负责制定董 事、高级管理人员的考核标准并进行考核，制定、审查董事、高级管理人员的 薪酬政策与方案,对董事会负责。 第三条 本规则所称董事是指在本公司支取薪酬的董事长、董事,高级管理 人员是指董事会聘任的总经理、副总经理、董事会秘书及由总经理提请董事会 认定的其他高级管理人员。 第二章 人员组成 第四条 薪 ...

战略委员会议事规则 （2024 年 4 月修订） 第一章 总则 第一条 为满足浙江海翔药业股份有限公司（以下简称"公司"）战略发展 需要,增强公司核心竞争力,确定公司发展规划,健全投资决策程序,加强决策科 学性,提高重大投资决策的效益和决策的质量,完善公司治理结构,根据《中华人 民共和国公司法》、《上市公司治理准则》、《公司章程》及其他有关规定,公司特 设立董事会战略委员会,并制定本议事规则。 浙江海翔药业股份有限公司 第二条 董事会战略委员会是董事会设立的专门工作机构,主要职责是对公 司长期发展战略和重大投资决策进行研究并提出建议。 第二章 人员组成 第三条 战略委员会由三名委员组成，委员均必须是公司董事。其中独立董 事应过半数。 第四条 战略委员会委员由董事长、二分之一以上独立董事或者全体董事的 三分之一提名，并由董事会选举产生。 第五条 战略委员会设主任委员一名,由非独立董事委员担任。 第六条 战略委员会任期与董事会任期一致,委员任期届满,连选可以连任。 期间如有委员不再担任公司董事职务,自动失去委员资格,并由委员会根据上述 第三至第五条规定补足委员人数。 第三章 职责权限 第七条 战略委员会的主要职责 ...

经核查公司全体独立董事的任职经历及其提交的相关自查文件，公司董事 会未发现可能影响独立董事进行独立客观判断的情形，并认为公司全体独立董 事继续保持独立性。 浙江海翔药业股份有限公司 董 事 会 二零二四年四月二十九日 浙江海翔药业股份有限公司董事会 关于独立董事独立性自查情况的专项评估意见 浙江海翔药业股份有限公司（以下简称"公司"）根据《公司法》、《证券 法》、《上市公司独立董事管理办法》等有关法律法规、规范性文件和公司《独 立董事工作制度》 的规定，公司第七届董事会现任独立董事俞永平、钱建民、 梁超对照相关监管规定中关于独立董事所应具备的独立性要求进行了逐项自 查，经董事会提名委员会审议通过了《关于审核 2023 年度独立董事独立性自查 情况的议案》，并向公司董事会提交了 2023 年度独立性自查表。经自查，公司 全体独立董事均确认其已满足公司适用的各项监管规定中对于出任公司独立董 事所应具备的独立性要求。 ...

证券代码：002099 证券简称：海翔药业 公告编号：2024-024 浙江海翔药业股份有限公司 关于为合并报表范围内子公司提供担保额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 浙江海翔药业股份有限公司（以下简称"公司"）第七届董事会第九次会议 审议通过了《关于为合并报表范围内子公司提供担保额度的议案》。具体情况公 告如下： 三、被担保人基本情况 一、担保情况概述 为满足合并报表范围子公司经营及发展的需要，公司拟为合并报表范围内 子公司提供担保额度，担保总额为90,500万元（或等值外币），其中为资产负 债率低于70%的合并报表范围内子公司提供合计35,500万元（或等值外币）担保 额度，为资产负债率高于70%的合并报表范围内子公司提供合计55,000万元（或 等值外币）担保额度，实际担保金额以正式签订的担保协议为准。本次担保范 围包括但不限于申请综合授信、借款、融资租赁等融资或开展其他日常经营业 务等；担保种类包括保证、抵押、质押等；担保方式包括直接担保或提供反担 保。担保额度的有效期自2023年年度股东大会审议通过之日起至2024年年度股 东 ...